Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab

Blood Adv. 2018 Aug 14;2(15):1865-1868. doi: 10.1182/bloodadvances.2018019000.

Abstract

  1. Cold agglutinin syndrome is one of the rare immune-related adverse events of nivolumab.

  2. Rituximab should be considered for treatment of nivolumab-induced cold agglutinin syndrome.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Anemia, Hemolytic, Autoimmune / chemically induced*
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Anemia, Hemolytic, Autoimmune / pathology*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Female
  • Gemcitabine
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / drug therapy
  • Lymphoma, B-Cell, Marginal Zone / pathology
  • Neoplasms, Second Primary / chemically induced
  • Neoplasms, Second Primary / drug therapy
  • Neoplasms, Second Primary / pathology
  • Nivolumab / administration & dosage
  • Nivolumab / adverse effects*
  • Rituximab / administration & dosage*
  • Syndrome

Substances

  • Deoxycytidine
  • Nivolumab
  • Rituximab
  • Carboplatin
  • Gemcitabine